Adrenomed closes € 24 M financing led by Wellington and HBM
- The financing round was led by top-tier life science venture capitalists Wellington Partners and HBM Healthcare Investments, joined by existing shareholders
- The new funds will be used to execute a proof-of-concept clinical program of lead product…
Call for Abstracts: 2nd German Mass Cytometry User Forum in Berlin
Extended deadline for abstract submissions: November 28, 2018
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide
Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in…
Eckert & Ziegler Q3/2018: Increase in Revenue in all Business Segments
Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, increased the earnings per share to €2.50 in the third quarter of 2018 and thus reached…
NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC
NOXXON ends the use of variable rate equity financing with Yorkville
TU Berlin: In focus: Peptides, the “little brothers and sisters” of proteins
A new Research Training Group aims to decode the complex structure of peptides. The German Research Foundation is to provide EUR 4.5 million in funding for the research
Revolutionizing the production of novel diagnostics with cost-effective Roll-to-Roll imprinting
R2R Biofluidics EU project recently received the Austrian Fast Forward Award 2018
OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation
Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks
ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded…